First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817 | Journal for ImmunoTherapy of Cancer
Comparisons between the CheckMate 227 trial and simulation, overall... | Download Scientific Diagram
CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in NSCLC - ILCN.org (ILCN/WCLC)
Pharmaceuticals | Free Full-Text | First line Immunotherapy for Non-Small Cell Lung Cancer
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - ScienceDirect
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 | Journal of Clinical Oncology
OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC
Overall survival in the Asian subpopulation, including Japanese... | Download Scientific Diagram
OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC | Nature Reviews Clinical Oncology
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden | NEJM
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer | NEJM
Defining patient groups for immunotherapy
First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations - Journal of
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1 - Journal of Thoracic Oncology
First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients - ScienceDirect
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update - ESMO Open
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. | Semantic
Forest plots for (a) overall survival and (b) progression-free survival... | Download Scientific Diagram
ASCO 2020 Lung Cancer Highlights - Journal of Oncology Navigation & Survivorship
Survival in non-small cell lung cancer patients with pre-treated and... | Download Scientific Diagram
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden | NEJM
Frontiers | Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
Best Practices: Practical Guidance in Treating Advanced NSCLC with Immunotherapy | Oncology Practice Management
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - ScienceDirect
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial - The Lancet Oncology
